免疫联合抗血管生成靶向一线治疗 晚期肝癌的临床疗效

Clinical efficacy of first-line immunotherapy plus anti-angiogenesis targeted therapy in the treatment of advanced hepatocellular carcinoma

  • 摘要: 肝癌具有高发病率和病死率,严重危害人类健康。目前已有多种靶向治疗药物获批用 于晚期肝癌的一线和二线治疗。免疫治疗的出现使肝癌治疗进入新时代。靶向治疗与免疫治疗药物 在机制上具有协同作用,两者联合使用可使部分晚期肝癌病人获益。同时,在免疫联合靶向的全身治 疗基础上增加适当的局部治疗,可使部分病人延长生存时间甚至获得治愈机会。笔者报道 1例免疫 联合抗血管生成靶向一线治疗晚期肝癌病人的临床疗效,其研究结果显示:病人治疗达到病理学完全 缓解,成功转化后行手术切除,预后良好,生命质量较高。

     

    Abstract: Hepatocellular carcinoma has a high morbidity and mortality, which has seriously harmed human health. Several targeted therapies have been approved for the first- and second-line treatment of advanced hepatocellular carcinoma. The emergence of immunotherapy has brought the treatment of hepatocellular carcinoma into a new era. Targeted and immunotherapeutic agents have synergistic effects in mechanism, also the combination of these two therapies has been clinically beneficial to patients with advanced hepatocellular carcinoma. At the same time, in addition to the systemic therapy of targeted combined immunological, applying appropriate local therapy can provide a longer survival period or even a chance of cure for that some patients. The authors introduce the diagnosis and treatment of a case of advanced hepatocellular carcinoma who achieved pathological complete remission by first-line immunotherapy combined with antiangiogenesis targeted therapy.

     

/

返回文章
返回